The year's new drugs and biologics 2018 : Part II - News that shaped the industry in 2018
Copyright 2019 Clarivate Analytics..
This eagle's-eye overview of the drug industry in 2018 provides insight into some of last year's top stories, including a large and still growing outbreak of Ebola in the Democratic Republic of the Congo, as well as the potential uses (and abuses) of CRISPR technology. As in previous years, we also review orphan drug development, new regulatory agency-supported programs such as Priority Medicines Scheme (PRIME) and Sakigake, pipeline attrition, and pharma/biotech mergers and acquisitions of note. Finally, we take a glimpse into the crystal ball to anticipate the new drugs that will be approved in 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 55(2019), 2 vom: 19. Feb., Seite 131-160 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Graul, A I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 16.05.2019 Date Revised 16.05.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2019.55.2.2974962 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29441312X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29441312X | ||
| 003 | DE-627 | ||
| 005 | 20231225081426.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2019.55.2.2974962 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0981.xml |
| 035 | |a (DE-627)NLM29441312X | ||
| 035 | |a (NLM)30816887 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Graul, A I |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The year's new drugs and biologics 2018 |b Part II - News that shaped the industry in 2018 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.05.2019 | ||
| 500 | |a Date Revised 16.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2019 Clarivate Analytics. | ||
| 520 | |a This eagle's-eye overview of the drug industry in 2018 provides insight into some of last year's top stories, including a large and still growing outbreak of Ebola in the Democratic Republic of the Congo, as well as the potential uses (and abuses) of CRISPR technology. As in previous years, we also review orphan drug development, new regulatory agency-supported programs such as Priority Medicines Scheme (PRIME) and Sakigake, pipeline attrition, and pharma/biotech mergers and acquisitions of note. Finally, we take a glimpse into the crystal ball to anticipate the new drugs that will be approved in 2019 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CRISPR-Cas9 | |
| 650 | 4 | |a Ebola | |
| 650 | 4 | |a Mergers and acquisitions | |
| 650 | 4 | |a Orphan drugs | |
| 650 | 4 | |a PRIME | |
| 650 | 4 | |a Pipeline | |
| 650 | 4 | |a Sakigake | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Dulsat, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pina, P |e verfasserin |4 aut | |
| 700 | 1 | |a Cruces, E |e verfasserin |4 aut | |
| 700 | 1 | |a Tracy, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 55(2019), 2 vom: 19. Feb., Seite 131-160 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2019 |g number:2 |g day:19 |g month:02 |g pages:131-160 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2019.55.2.2974962 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2019 |e 2 |b 19 |c 02 |h 131-160 | ||